Telapristone
Template:Short description Template:Drugbox
Telapristone (INN), as telapristone acetate (proposed brand names Proellex, Progenta; former code name CDB-4124), is a synthetic, steroidal selective progesterone receptor modulator (SPRM) related to mifepristone which is under development by Repros Therapeutics for the treatment of breast cancer, endometriosis, and uterine fibroids.[1][2] It was originally developed by the National Institutes of Health (NIH), and, as of 2017, is in phase II clinical trials for the aforementioned indications.[1] In addition to its activity as an SPRM, the drug also has some antiglucocorticoid activity.[3]
See also
- List of investigational sex-hormonal agents § Progestogenics
- Aglepristone
- Lilopristone
- Onapristone
- Toripristone
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".
External links
Template:Progestogens and antiprogestogens
Template:Progesterone receptor modulators
Template:Glucocorticoid receptor modulators